In 2022, Triad Life Sciences was acquired by Convatec Group PLC — a British medical and technologies company — and adopted the name Convatec Advanced Tissue Technologies.
Founded in 2017, the Memphis-based biotech business had created InnovaMatrix AC, a wound care product that was the first placenta-derived medical device approved by the FDA for wound management.
And now, with its new name, the organization has had another product clear that hurdle.
InnovaMatrix PD has received FDA clearance to be used for wound management. According to a press release, it joins InnovaMatrix AC as the only placental-derived medical devices designed for management of complex surgical wounds, chronic stalled wounds, and burns.
"Convatec is always proud to bring healing innovations to patients with hard-to-heal wounds," said David Shepherd, president and COO of advanced wound care at Convatec, in the release. "We're pleased to offer physicians this new particulate product that is the first of its kind.”
The product is now commercially available, and it can be used to treat traumatic lacerations, dehisced incisional wounds, pressure and venous ulcers, post-Mohs surgery wounds, partial thickness burns, surgical incisions, and diabetic foot ulcers.
It’s also been controlled for genetic variability and lifestyle factors — like diet and activity levels — and it doesn’t require preparation, tissue tracking, or special storage.
“Physicians tell us they are excited to have a particulate placental-derived product that can support the healing process for patients with complicated wounds,” said Divakar Ramakrishnan, Convatec’s chief technology officer, in the release.
